ArticleSkin health and disease2025
Topical corticosteroid phobia among caregivers: a study in atopic and nonatopic dermatitis children by using the TOPICOP score.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Treatment Patterns and Determinants of Therapy in Pediatric Atopic Dermatitis: A 10-Year Experience from a Tertiary Referral Center in Thailand.Children (Basel, Switzerland) · 2026Article
- Development and Rasch Validation of the Parental Topical Corticosteroid Phobia Scale (PTCPS) in Pediatric Eczema Care.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Topical corticosteroids (TCS) are a standard treatment for many inflammatory cutaneous conditions; however, patients frequently suffer corticophobia, or fears about TCS side effects. Patients' fear of TCS can prevent them from taking the medication properly, which might have an impact on disease control, particularly for chronic conditions such as atopic dermatitis. Objectives: To evaluate topical corticophobia among caregivers of children diagnosed with atopic dermatitis and other skin disorders treated with TCS, using the TOPICOP score. The research additionally investigated factors related to corticophobia within the study group. Methods: A cross-sectional study was conducted at the Pediatric Department, Faculty of Medicine, Khon Kaen University, Thailand, from April 2023 to January 2024. Parents of children visiting the dermatology clinic involving TCS were asked to complete the questionnaire. Results: The study included 320 parents of children with skin conditions. There were 251 women (78.4%) and 69 men (21.6%). The mean age was 35 years (SD 8.13). The mean age of the children in the study was 5.64 years (SD 4.69). Median Global TOPICOP score was 52.78% (interquartile range 41.69-69.44). Parents with children with atopic dermatitis had a higher median global TOPICOP score of 63.89%, whereas those with other skin disorders had a lower score of 44.44%. Men, parents over 35 years old and parents with less than a bachelor's degree showed lower corticophobia than women, younger parents and those with greater education. Conclusions: The present study indicated that long-term diseases such atopic dermatitis caused more anxiety regarding TCS use than other skin problems. The face and periorbital were more vulnerable to TCS. Parents with higher education reported increased concern regarding TCS usage in Thai settings; thus, parents and caregivers, especially those with children with atopic dermatitis, should get appropriate TCS advice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.